Dianthus Therapeutics (DNTH) Net Cash Flow (2017 - 2025)

Dianthus Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at $42.7 million for Q3 2025.

• On a quarterly basis, Net Cash Flow rose 115.23% year-over-year to $42.7 million in Q3 2025; TTM through Dec 2025 was $33.1 million, a 130.29% increase from a year earlier, with the FY2024 full-year figure at -$109.4 million, down 193.5% from the prior year.
• Net Cash Flow grew to $42.7 million in Q3 2025 per DNTH's latest filing, from $3.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $197.4 million in Q1 2024 and bottomed at -$280.3 million in Q3 2024.
• The 5-year median for Net Cash Flow is -$8.9 million (2021), against an average of $6.4 million.
• Biggest YoY gain for Net Cash Flow was 4136.37% in 2022; the steepest drop was 575.67% in 2022.
• Year by year, Net Cash Flow stood at -$25.9 million in 2021, then increased by 16.89% to -$21.5 million in 2022, then slipped by 15.99% to -$25.0 million in 2023, then surged by 56.41% to -$10.9 million in 2024, then surged by 492.38% to $42.7 million in 2025.
• Per Business Quant, the three latest DNTH Net Cash Flow figures stand at $42.7 million (Q3 2025), $3.1 million (Q2 2025), and -$12.7 million (Q1 2025).